文献速递免疫规划

DTaP初免青少年对两种Tdap疫苗的免疫应答随机研究及与DTwP初免者的比较

Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP.
PubMed 文献 · Vaccine · 2019-07-10

研究将11-12岁且7岁前完成5剂DTaP的青少年随机分配接种两种Tdap疫苗,检测前后血清抗体,并与同实验室既往DTwP初免青少年Tdap研究比较。结果显示两种Tdap均诱导强烈的白喉和破伤风抗体应答,但DTaP初免者接种后百日咳抗体应答较DTwP初免者最多低71%。

要点

  • DTaP初免青少年接种Tdap后百日咳抗体应答较DTwP初免者最多低71%。
  • 两种Tdap均诱导强烈的白喉和破伤风抗体应答。
  • 百日咳抗原抗体应答与各Tdap疫苗中抗原含量差异一致。

核心结论

  • 随机临床试验直接证据表明,与DTwP初免青少年相比,DTaP初免青少年对两种 licensed Tdap疫苗的抗体应答降低。

研究设计与样本

  • 2012年将11-12岁且7岁前接受 exactly 5剂DTaP的青少年随机分配接种两种 licensed Tdap疫苗之一,检测接种前后血清抗体,并与同实验室既往DTwP或DTaP初免青少年的随机Tdap研究结果比较。

主要发现

  • 两种Tdap疫苗均产生强烈的白喉和破伤风抗体应答。
  • 对所含百日咳抗原的应答与各Tdap疫苗中相应抗原水平差异一致。
  • DTaP初免青少年接种后百日咳抗体应答较既往同两种Tdap疫苗研究中DTwP初免青少年最多低71%。
  • 本研究结果与另一项DTaP初免青少年Tdap研究结果相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It has been reported that persons primed with acellular (DTaP) pertussis vaccines have reduced duration of pertussis protection compared with those primed with whole-cell (DTwP) vaccines. However, due to the rapid transition to acellular vaccines, studies attempting directly to compare protection among DTaP-primed vs DTwP-primed individuals are subject to confounding by age and other limitations of ecological studies. Using validated assay results and stored sera from multiple Tdap studies, we evaluated two licensed Tdap vaccines among DTaP-primed adolescents to allow comparison with results obtained in the same laboratory from earlier studies involving DTwP-primed adolescents. METHODS: Participants 11-12 years of age who had received exactly 5 doses of DTaP vaccine prior to 7 years of age were randomly assigned in 2012 to receive one of two licensed Tdap vaccines. Serum specimens obtained pre- and post-vaccination were assayed for responses to the vaccines. Current results were then compared to results obtained in the same laboratory from prior randomized Tdap studies conducted among adolescents primed with DTwP or DTaP. RESULTS: Both Tdap vaccines produced strong antibody responses to diphtheria and tetanus; responses to contained pertussis antigens were consistent with the differing levels of those antigens in each Tdap vaccine. However, postvaccination pertussis antibody responses were as much as 71% lower in these DTaP-primed adolescents compared with responses among DTwP-primed adolescents in a prior study of the same two Tdap vaccines. In contrast, results from the present study were similar to those seen in another study of Tdap among DTaP-primed adolescents. DISCUSSION: Taken together, these results from randomized clinical trials provide direct evidence of reduced antibody responses to both licensed Tdap vaccines among adolescents primed with DTaP vaccine, compared with adolescents primed with DTwP vaccine. Clinical trial registry number: ClinicalTrials.gov, NCT01629589.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Decker MD, Greenberg DP, Johnson DR, et al. Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP. Vaccine. 2019. PMID: 31301919. doi:10.1016/j.vaccine.2019.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。